Whitney Ijem

Stock Analyst at Canaccord Genuity

(0)
# 4464
Out of 5,291 analysts
101
Total ratings
33.33%
Success rate
-14.99%
Average return
21 Stocks
Name Action Price Target Current % Upside Ratings Updated
Alnylam Pharmaceutic...
Maintains: Strong Buy
385 390
268.5 45.25% 8 Mar 21, 2025
Regulus Therapeutics
Maintains: Buy
28 28
1.72 1527.91% 5 Mar 17, 2025
Generation Bio
Maintains: Buy
9 9
0.43 1993.02% 2 Mar 17, 2025
Tenaya Therapeutics
Maintains: Buy
18 6
0.64 837.5% 6 Mar 13, 2025
Arcturus Therapeutic...
Maintains: Buy
74 68
11.58 487.22% 5 Mar 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
39 36
7.58 374.93% 6 Mar 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
80 81
54.8 47.81% 6 Feb 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
39 39
27.84 40.09% 2 Feb 26, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
121 136
37.8 259.79% 8 Feb 18, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Hold
408 424
492.19 -13.85% 8 Feb 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
90 90
8.06 1016.63% 5 Nov 19, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
6 8
1.93 314.51% 8 Nov 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
13 13
0.38 3321.05% 6 Nov 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
148 150
70.41 113.04% 3 Nov 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
29 32
5.21 514.2% 4 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
93 84
71.4 17.65% 8 Oct 30, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
6 30
n/a n/a 2 Jul 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
260
n/a n/a 1 Feb 7, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Jan 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
120 240
4.2 5614.29% 4 Jul 23, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
33 0
n/a n/a 2 Feb 26, 2018